Singleton Mark Leonard 4

What Happened

• Mark Leonard Singleton, SVP & CFO of Bioventus Inc. (BVS), exercised/converted 13,500 derivative units into shares on 2026-03-13. To cover tax withholding related to the transaction, 5,865 shares were surrendered/withheld at $8.62 per share for a total of $50,556.
• The filing also reports several equity awards (RSUs/options) granted to Singleton: 54,000 and 61,000 on 2025-03-14, and 104,000 and 116,000 on 2026-03-13 — a total of 335,000 award units (issued as derivatives/RSUs at $0 acquisition price).

Key Details

• Transaction types/dates:
  • 2026-03-13: Exercise/conversion of 13,500 derivative units (code M).
  • 2026-03-13: 5,865 shares withheld/surrendered for tax liability at $8.62 each (code F), total $50,556.
  • Grants (code A): 54,000 and 61,000 awarded on 2025-03-14; 104,000 and 116,000 awarded on 2026-03-13.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU converts to one share of Class A common stock. F2/F3 — the RSUs/options vest in four equal annual installments beginning March 15, 2025 (for the 2025 awards) and March 15, 2026 (for the 2026 awards), subject to continued service.
• Timeliness: The report covering a 2025-03-14 award was filed on 2026-03-17, indicating a late filing relative to the usual two-business-day Form 4 deadline.

Context

• The 13,500-unit conversion appears to be an exercise/conversion of derivative awards; the withholding of 5,865 shares to cover taxes is a routine cashless tax-withholding action, not an open-market sale.
• The large RSU/option grants are standard compensation awards that vest over four years and do not by themselves indicate immediate buying or selling intent.
• These entries are compensation-related (awards and exercise/conversion) rather than discretionary open-market purchases by the insider.